Literature DB >> 1375250

Cells expressing an H chain Ig gene carrying a viral T cell epitope are lysed by specific cytolytic T cells.

H Zaghouani1, M Krystal, H Kuzu, T Moran, H Shah, Y Kuzu, J Schulman, C Bona.   

Abstract

The epitope corresponding to amino acid residues 147-161 of the nucleoprotein (NP) of influenza A virus is recognized by CTL in association with H-2Kd class I Ag. Herein, we engineered an Ig molecule carrying this CTL epitope by replacing the diversity gene segment of the H chain V region of an anti-arsonate antibody with an oligonucleotide that encodes the CTL epitope. The chimeric H chain gene was expressed either alone or together with the parental L chain in the nonsecreting BALB/c myeloma B cell line, SP2/0. The Ig produced by cells transfected with both the chimeric H chain and parental L chains genes expressed the NP epitope but lost the original arsonate binding activity. In addition, SP2/0 cells expressing the chimeric H chain either alone or together with the parental L chain were lysed by class I restricted NP-epitope specific CTL. By contrast, SP2/0 cells pulsed with soluble chimeric Ig molecules were not lysed by the specific CTL. These observations indicate that: 1) this particular CTL epitope can be expressed on Ig molecules without altering the H and L chain pairing; 2) this CTL epitope can be generated from this chimeric Ig in which it is surrounded by flanking regions distinct from those of the viral NP; and 3) the generation of this CTL epitope from the Ig molecule requires the endogenous pathway as do viral proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375250

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

Authors:  I B Rasmussen; E Lunde; T E Michaelsen; B Bogen; I Sandlie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1.

Authors:  S Li; V Polonis; H Isobe; H Zaghouani; R Guinea; T Moran; C Bona; P Palese
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

3.  Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.

Authors:  H Zaghouani; S A Anderson; K E Sperber; C Daian; R C Kennedy; L Mayer; C A Bona
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

4.  Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus.

Authors:  T D Brumeanu; W J Swiggard; R M Steinman; C A Bona; H Zaghouani
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

5.  Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processing.

Authors:  K L Legge; B Min; N T Potter; H Zaghouani
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

Review 6.  Immunogenic properties of immunoglobulin superfamily members within complex biological networks.

Authors:  Josué Odales; Jesus Guzman Valle; Fernando Martínez-Cortés; Karen Manoutcharian
Journal:  Cell Immunol       Date:  2020-10-11       Impact factor: 4.868

7.  P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties.

Authors:  Darel Martínez; Nely Rodríguez; Tania Griñán; Teresa Rondón; Ana María Vázquez; Rolando Pérez; Ana María Hernández
Journal:  Front Immunol       Date:  2012-04-26       Impact factor: 7.561

8.  Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergy.

Authors:  B Min; K L Legge; C Pack; H Zaghouani
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

9.  Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant.

Authors:  H Isobe; T Moran; S Li; A Young; S Nathenson; P Palese; C Bona
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.